Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3693731 | 0.82 | KDM4E (0.52) | KDM4EHTTLMNACYP2D6TSHR | |
| SCHEMBL2316901 | 0.82 | CYP2D6 (0.82) | KDM4ELMNAUSP2ALDH1A1GAA | |
| Medibazine SCHEMBL308996 | 0.82 | OPRD1 (0.70) | KDM4ELMNAUSP2ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL1681495 | 0.82 | KDM4E (0.53) | KDM4EHTTLMNAMAPTCYP2D6 | |
| SCHEMBL4750981 | 0.81 | CYP2D6 (0.59) | KDM4ELMNAUSP2ALDH1A1GAA | |
| Medibazine SCHEMBL7321169 | 0.81 | OPRD1 (0.69) | KDM4EHTTLMNAMAPTUSP2 | |
| SCHEMBL108678 | 0.81 | KDM4E (0.70) | KDM4EUSP2CYP2D6TSHRHSD17B10 | |
| SCHEMBL7267761 | 0.80 | KDM4E (0.65) | KDM4EHTTLMNAALDH1A1GAA | |
| SCHEMBL4465545 | 0.79 | KDM4E (1.00) | KDM4EHTTLMNAGAA | |
| SCHEMBL4468044 | 0.79 | KDM4E (1.00) | KDM4EHTTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576086-B2 | N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2009-08-18 | — | — | US | claimed |
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-12-01 | — | — | US | claimed |
| US-7576086-B2 | N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2009-08-18 | — | — | US | disclosed |
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | AANAT, GAP43, TPH2 | KDM4E 2865/4885HTT 1379/4885LMNA 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.